Cannabis News

Medical Marijuana, Inc. Launches Pharma Subsidiary in Brazil; Expands Access to CBD Products in Pharmacies

SAN DIEGO, Calif., May 26, 2022 (GLOBE NEWSWIRE) — via NewMediaWire Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chains, announced today today the launch of its first pharmaceutical subsidiary, HM-Pharmain Brazil.

“We have worked hard to connect and build meaningful relationships with healthcare professionals and consumers in Brazil. This new sales channel will open new avenues for continued growth by bringing our cannabidiol (CBD) products to pharmacies across the country,” said Matheus Patelli, Managing Director of HM Pharma. “Not only will our products be more affordable than other CBD products sold in pharmacies in Brazil, but they will be of the highest quality.”

In Brazil, CBD is currently only authorized for medical purposes with the authorization of the country’s National Health Surveillance Agency (Anvisa). HM Pharma will operate under Anvisa Normative 327/2019 which allows the company to sell its products in pharmacies. Customers will soon have the choice of purchasing HM Pharma at a point-of-sale pharmacy with a medical prescription or continuing to order from HempMeds® Brasil using Brazil’s compassionate use law. The company expects HM Pharma products to be on pharmacy shelves by the end of 2022.

HempMeds® Brasil, a subsidiary of Medical Marijuana, Inc., was the first company to legally import products into Brazil in 2015 using Brazil’s compassionate use laws. The compassionate use market in Brazil is flourishing and will continue to coexist with the medical market. HempMeds® Brasil, which is currently growing 75.8% faster than the entire Brazilian CBD market and is one of the largest players in the Brazilian cannabis industry, will continue to operate under the model of compassionate use, while HM Pharma will operate under Anvisa Normative 327/2019.

“HempMeds Brazil has imported over 150,000 prescription products to Brazil through the compassionate model since 2015, and we continue to grow at an average rate of 50% per year. Our market leadership reflects the quality of our products, our customer service and our relationships with physicians,” added Patelli.

“Brazil has led the way in Latin American expansion for Medical Marijuana, Inc. We are confident that this will continue as we enter the pharmaceutical space,” said the CEO of Medical Marijuana, Inc. , Blake Schroeder. “HM Pharma has great potential to add significant value to our shareholders and will enable greater free access to cannabis-based medicines to Brazilian consumers than ever before.”

About Medical Marijuana, Inc.

We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct non-psychoactive cannabinoid business units: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in providing the highest quality non-psychoactive legal cannabis products derived from industrial hemp; and a clinical research and development sector for cannabinoid-based botanical drugs led by its pharmaceutical investment companies and partners, including AXIM® Biotechnologies, Inc.. and Neuropathix. Medical Marijuana, Inc. was named one of the top CBD producers by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina and Paraguay and is a leader in developing international markets. The company’s flagship product Genuine Scientific Hemp Oil has been used in several successful clinical studies in Mexico and Brazil to understand its safety and effectiveness.

Medical Marijuana, Inc. is headquartered in San Diego, CA and additional information is available at or by visiting To view the Medical Marijuana, Inc. corporate video, Click here.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by these articles. This document contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. These forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to differ materially from the statements made herein.


These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.


Medical Marijuana, Inc. does not sell or distribute products that violate the US Controlled Substances Act.

Public relations contact:
Katherine Brown
Account director
CMW Media
[email protected]
Contact with Investor Relations:
T. (858) 283-4016
[email protected]

#Medical #Marijuana #Launches #Pharma #Subsidiary #Brazil #Expands #Access #CBD #Products #Pharmacies

Related Posts

Leave a Reply